key: cord-0828182-6yx3vuh9 authors: Ghaffari Rahbar, Maryam; Nafar, Mohsen; Khoshdel, Alireza; Dalili, Nooshin; Abrishami, Alireza; Firouzan, Ahmad; Poorrezagholi, Fatemeh; Samadian, Fariba; Ziaie, Shadi; Fatemizadeh, Somayeh; Samavat, Shiva title: Low rate of COVID‐19 pneumonia in kidney transplant recipients—A battle between infection and immune response? date: 2020-07-21 journal: Transpl Infect Dis DOI: 10.1111/tid.13406 sha: fffc2cc19b86ddf20cfda2934854909cac98667e doc_id: 828182 cord_uid: 6yx3vuh9 BACKGROUND: With COVID‐19 pandemic, concerns about kidney transplant recipients are rising. However, the incidence, clinical course, outcome, and predictive factors of disease severity are obscured. METHODS: We describe clinical and laboratory manifestations, radiologic findings, clinical course, and finally outcome of kidney transplant recipients with COVID‐19 pneumonia. RESULTS: Of 2493 kidney transplant recipients under follow‐up in our clinic, 19 cases (4 cases diagnosed based on radiologic findings) were admitted. The mean age of patients was 47.6 ± 12.4 years, and the mean time from transplantation was 115.6 ± 70.3 months. Lymphopenia and eosinopenia were 84.2% and 78.9%, respectively. Nine patients did not survive the hospital course. History of acute rejection during the past 12 months, diabetes, higher N/L ratio, lower platelet count, elevated N/L x CRP, higher levels of LDH, positive D‐dimer, higher troponin, and prolonged PT were associated with mortality. Among patients with positive COVID‐19 test, history of acute rejection, low platelet count, and positive D‐dimer were associated with poor outcome. Treatment with cyclosporine was associated with better clinical outcome. CONCLUSIONS: Low rate of admission in transplant recipients specially in the very first years of transplantation might be due to protective effects of immunosuppressive agents against cytokine storm or modification of immunity function. We suggest evaluation of T‐cell number, function, and cytokine profile as a guide to manage COVID‐19 mainly in patients with higher risk of mortality. Following the outbreak of novel corona virus infection in the late December 2019 in China and its spread throughout the world, the disease was first reported in Iran on 20th of February 2020. Since then more than 85 000 have been diagnosed and 5297 had lost their lives in the country. (By April 22nd, 2020). According to the literature, older patients and those with comorbidities such as diabetes, hypertension, cardiovascular diseases, obesity, and immunosuppressed patients are at higher risk of morbidity and mortality. 1 Kidney transplant recipients are in a chronic immunosuppressive state, which theoretically might pose them to the higher risk of complications, uncommon presentations, and worse outcome comparing with general population. Nevertheless, the incidence, clinical course, and outcome of COVID-19 are not clear in this population. The aim of our study was to report clinical manifestations, laboratory findings, disease course, and outcome of 19 kidney transplant recipients who were admitted in Labbafinejad Medical Center from 20th February 2020 till 15th of April 2020. In Labbafinejad Medical Center, we perform around 200 kidney transplantation per year (nearly 60% of them from deceased donors). Of 2493 patients that are currently followed by active clinical or phone surveillance, 19 kidney transplant recipients were admitted with the diagnosis of COVID-19 from 20th February 2020 till 15th of April 2020. We described the clinical and laboratory manifestations, radiologic findings, clinical course, and outcome of these patients. All adult kidney transplant recipients who were admitted to our center were enrolled. Oro-or nasopharyngeal swabs were taken at presentation. Demographic data including age, gender, comorbidities, graft characteristics, and maintenance immunosuppressive therapy were extracted from patients' files. History of treatment for acute rejection episode during the past 12 months was registered. Clinical presentations and laboratory and radiologic findings were recorded. Laboratory assessments consisted of complete blood count, and differential cell count, serum creatinine, aspartate aminotransferase (AST) and alanine aminotransferase (ALT), serum albumin, ferritin, troponin, D-dimer, coagulation testing, C-reactive protein (CRP), lactate dehydrogenase (LDH), creatine kinase (CPK), and pH. Bacterial infections were ruled out by taking blood and urine cultures. IL-6 and fibrinogen were assessed. Allograft function was evaluated by creatinine-based MDRD equation of eGFR. Initial chest CT scans were interpreted by two independent radiologists. Predominant pattern of involvement, percentage of the lobar involvement, extension of involvement (Unilateral/ Bilateral), total lung score, and percentage of lung involvement were reported ( Figure 1 ). Clinical course, ICU admission, type of ventilatory support, vasopressor requirement, and the outcome of hospitalized COVID-19 patients were evaluated. Outcomes considered as admission to an intensive care unit, death, or discharge from the hospital. Patients were treated according to the protocol with antiviral treatment and immunosuppressive dose reduction (discontinuation of antimetabolites, CNI dose reduction in normoxemic patients and discontinuation among hypoxemic patients), prednisolone 20 mg daily or methylprednisolone 40 mg daily in normoxemia and hypoxemic patients, respectively, and IVIG 1-2 g/kg over 5 days in hypoxemic patients. 2 The antiviral therapy dosing was as followed: (a) hydroxychloroquine 200 mg twice daily in patients who were not treated with lopinavir/ritonavir, and 400 mg on day one in those treated with lopinavir/ritonavir; (b) lopinavir/ritonavir 400/100 mg twice daily; (c) favipiravir 1600 mg on day one and then 600 mg twice daily; (d) oseltamivir 75 mg twice daily (adjusted based on eGFR); and (e) ribaverin 1200 mg twice daily (adjusted based on eGFR). The duration of treatment was 7-10 days. Out of about 2500 kidney transplant recipients under follow-up in our center, only 19 patients were admitted with diagnosis of Patients' demographic and clinical manifestations are demonstrated in Only three allograft recipients had been treated with plasmapheresis, IVIG, and rituximab for chronic active antibody-mediated rejection during the past 12-month prior to admission. Two of them experienced rejection within a month of COVID-19 infection and one, 6 months earlier. Maintenance immunosuppressive regimen was cyclosporin, MMF/MPA and prednisolone in 9 (47.4%), tacrolimus, MMF/MPA and prednisolone in 7 (36.8%), and sirolimus, MMF/MPA and prednisolone in 3 (15.8%). About 58% of our cases were treated with angiotensin receptor blockers (ARBs). Alive (N = 10) Age (mean ± SD), y 47. 6 ARBs, n (%) 11 (57.9) 5 (55.6) 6 (60.0) .84 Abbreviations: ARBs, angiotensin receptor blockers; eGFR, estimated glomerular filtration rate; MMF/MPA, mycophenolate mofetil/mycophenolic acid. In the study population, 53% had comorbidities (21% diabetes, 32% hypertension). The most common clinical manifestation at the onset of illness was fever (73.7%), followed by dry cough and dyspnea (68.4% and 52.6%, respectively). None of our cases had experienced gastrointestinal symptoms or anosmia. 89.5% of patients were hypoxemic (O2 saturation < 93% at ambient air) at presentation. On the day of admission, 84.2% of patients had lymphopenia which was defined as lymphocyte count less than 1100 per mm 3 . Fifteen patients underwent lung CT scan early in the course of disease. The images were interpreted by two radiologists, independently (Table 3) . Two-thirds of patients had bilateral lung involvement with either ground-glass opacities or consolidation or both. None of our cases had cavitation, cystic changes, and lymphadenopathy. Three patients had pleural or pericardial effusion or both. Sixteen patients with low-dose CT scan were followed up with portable X-ray. Progression in lung involvement was found in serial CXRs. Of total 19 patients, 10 (52.6%) were admitted to ICU, 9 (47.7%) of GG score, mean ± SD 6.9 (4.7) 9. We analyzed those patients with positive COVID PCR by omitting four patients with only radiologic diagnosis. Comparing the demographic, clinical, laboratory, and radiologic findings of patients who survived and those who did not, the results were as followed. History of acute rejection during the past 12 months (P value .03), lower platelet count (P value .008), and positive D-dimer (P value .04) were still associated with poor outcome. Treatment with cyclosporine was more common among those who survived the course of disease (P value .02). Male gender and high LDH levels were more common in those who did not survive, although not statistically significant (P value .06). The degree of CT scan lung involvement was greater among non-survivors. The results are displayed in Table 5 . Nearly 73% of our cases had AKI at presentation, even before initiation of antiviral treatment. In various case series of patients with either transplanted or native kidneys, the incidence of AKI was about 40%. [9] [10] [11] The low incidence of disease could be on one hand due to respecting the social distancing rules by this group, or due to the fact that some levels of immunosuppression could protect them against the severe immunologic response, cytokine storm, and viral replica- 14, 15 Hence, the maintenance therapy with CNIs might play a protective role in transplanted patients. In this cohort, we did not have patients with history of transplantation of less than 2 years, as was the case with the Italian series. 16 The low rate of admission in transplant recipients specially in the first years of transplantation might be due to protective effects of immunosuppressive agents against cytokine storm or modification of immunity function. However, most centers including ours 2 stop the antimetabolite and significantly reduce the CNI level or even stop it, and keep the steroids, which was based on a low level of evidence. Despite discontinuation of CNI and antimetabolites in severe and hypoxemic cases and early initiation of antiviral treatment upon admission and treatment with IVIG (1-2 g/kg), the mortality rate was 45% in our center. This high mortality rate could be due to more severe disease among this population as noted in series of 20 patients in Italy, 16 Although transplant recipients seem to be affected less with severe type of disease (only 19 patients out of about 2500), which might be due to some levels of immunosuppression, patients who had a history of acute rejection and recent immunosuppressive intensification had worse outcomes. One of the major limitations of our study was the small sample size. A larger cohort in a multicenter study may help to drive a more solid conclusion. In conclusion, COVID-19 is a mysterious disease that presented as an infectious disease and evolved to a state of immunologic disturbances. Thereby, management of COVID-19 is a state of art, with initiation of antiviral therapy in early steps and thoughtful usage of immunosuppressive drugs. We acknowledge the efforts of our treatment and laboratory team in management of patients. Abbreviations: CC, consolidation; GG, ground-glass; MMF/MPA, mycophenolate mofetil/mycophenolic acid; N/L, neutrophil to lymphocyte ratio. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China COVID-19 Rapid guideline in kidney transplant recipients Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Correlation of chest CT and RT-PCR Testing for coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases Essentials for radiologists on COVID-19: an update-radiology scientific expert panel Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2 Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression Acute kidney injury in patients hospitalized with COVID-19 Covid-19 and kidney transplantation Early description of coronavirus 2019 disease in kidney transplant recipients in New York Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506 COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal Why the immune system fails to mount an adaptive immune response to a Covid -19 infection Reducing mortality from 2019-nCoV: host-directed therapies should be an option A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 COVID-19: immunopathology and its implications for therapy Authors disclose no conflict of interest.